Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Targeting MCL1-mediated survival to overcome HMA resistance in CMML

Guillermo Montalban-Bravo • 15 Jun 2024
EHA 2024
Chronic Myelomonocytic Leukemia Leukemia Rare Diseases Venetoclax

Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the targeting of MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent (HMA) resistance in chronic myelomonocytic leukemia (CMML) with RAS pathway mutations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research support: Takeda Oncology, IFM Therapeutics, Solu Therapeutics.

More from Guillermo Montalban-Bravo

Refining the diagnosis and classification of CMML
6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
Anand Patel et al. • 15 Oct 2024
Clinical implications of extramedullary manifestations in CMML
1:12
Clinical implications of extramedullary manifestations in CMML
Guillermo Montalban-Bravo • 15 Jun 2024
A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML
1:37
A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML
Guillermo Montalban-Bravo • 15 Jun 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals